Everomus 0.25mg Tablet

Tablet
Rs.454for 1 strip(s) (10 tablets each)
1
எதிர்பாராதவிதமாக, எங்களிடம் எந்த இருப்பும் இல்லை.
அறிக்கை பிழை

Everomus 0.25mg Tablet க்கான கலவை

Everolimus(0.25mg)

Everomus Tablet க்கான உணவு இடைவினை

Everomus Tablet க்கான மது இடைவினை

Everomus Tablet க்கான கர்ப்பகாலம் இடைவினை

Everomus Tablet க்கான பால் புகட்டுதல் இடைவினை

உணவு
மது
கர்ப்பகாலம்
பால் புகட்டுதல்
Everomus 0.25mg Tablet may be taken with or without food.
None
CAUTION
It is not known whether it is safe to consume alcohol with Everomus 0.25mg Tablet. Please consult your doctor.
CONSULT YOUR DOCTOR
Everomus 0.25mg Tablet is not recommended during pregnancy as there is positive evidence of fetal risk based on animal studies. However, it may still be prescribed by a doctor in situations where the benefits outweigh the risks.
CONSULT YOUR DOCTOR
Everomus 0.25mg Tablet may be unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. It should be used only if the expected benefit outweighs the potential risk. Please consult your doctor.
CONSULT YOUR DOCTOR

Everomus 0.25mg Tablet க்கான உப்பு தகவல்

Everolimus(0.25mg)

Everomus tablet இன் பயன்கள்

Everomus tablet எப்படி வேலை செய்கிறது

Everomus 0.25mg Tablet is an mTOR (mammalian target of rapamycin) inhibitor. It works by blocking the activity of mTOR, a protein involved in cell growth, division, and survival. In cancer, it helps slow down the growth and multiplication of cancer cells. In organ transplant patients, it suppresses the activity of certain immune cells, particularly T-cells, helping prevent the immune system from attacking and rejecting the transplanted organ.

Everomus tablet இன் பொதுவான பக்க விளைவுகள்

Stomatitis (Inflammation of the mouth), Nausea, Anemia (low number of red blood cells), Infection, Rash, Fatigue, Diarrhea, Edema (swelling), Cough, Headache, Decreased appetite

Everomus Tablet க்கான மாற்றுகள்

Sorted By
RelevancePrice

Everomus Tablet க்கான நிபுணர் அறிவுரை

  • Everolimus is given for the treatment of certain cancers and to prevent organ transplant rejection. 
  • Everolimus may affect male or female fertility; consult your doctor if you are planning to have a child.
  • Inform your doctor straight away if you think you are getting a sore throat or if you have a high temperature. This is because Everolimus increases your risk of getting an infection.
  • While you are taking Everolimus do not take any vaccinations without talking to your doctor first.
  • If you are having an operation or dental treatment, always tell the person carrying out the treatment that you are taking Everolimus.
  • Do not drink grapefruit juice while you are taking this medicine. This is because a chemical in grapefruit juice can interfere with the action of Everolimus.

Everomus 0.25mg Tablet க்கான அடிக்கடி கேட்கப்படும் கேள்விகள்

Everolimus

Q. Is Everomus 0.25mg Tablet a chemotherapy?
Everomus 0.25mg Tablet is an anticancer medicine. It belongs to kinase inhibitor class of medicines. It works by reducing the blood supply to the tumor, which slows down the growth and spread of cancer cells.
Q. How is Everomus 0.25mg Tablet administered?
Usually, Everomus 0.25mg Tablet is taken once or twice daily. The medicine should always either be taken with food or always be taken without food. Everomus 0.25mg Tablet should be swallowed whole with water and should not be crushed or chewed.
Q. How long can you take Everomus 0.25mg Tablet?
There is no definite duration of treatment with Everomus 0.25mg Tablet. Everomus 0.25mg Tablet is continued till clinical benefit is seen or unacceptable toxicity or side effects occur.
Show More
Q. What should I avoid while taking Everomus 0.25mg Tablet?
You should avoid grapefruit or grapefruit juice while taking Everomus 0.25mg Tablet. This is because taking them together may increase the levels of Everomus 0.25mg Tablet in your blood to harmful levels. Avoid the use of live vaccinations and any possible contact with individuals who have received live vaccinations.
Q. What is the most important information I need to know about Everomus 0.25mg Tablet?
Everomus 0.25mg Tablet can cause serious side effects which include severe allergic reactions, angioedema, and kidney failure which can be severe and can lead to death. It is possible that you may develop an infection or problems related to lung such as breathing problems.
Q. How will I know that Everomus 0.25mg Tablet is shrinking my brain tumor?
The effect of Everomus 0.25mg Tablet in shrinking the size of tumor can only be checked by getting regular brain scans. It should be done as advised by your doctor and your treatment plan.
Q. Is Everomus 0.25mg Tablet cytotoxic?
Yes, Everomus 0.25mg Tablet is cytotoxic against human cancer cells of breast, stomach, prostate, and kidneys (renal cell carcinoma).
Q. Is any monitoring required while taking Everomus 0.25mg Tablet?
Regular monitoring is required while you are on Everomus 0.25mg Tablet. The doctor will advise blood tests to see the counts of red blood cells, white blood cells, and platelets since the counts may decrease during treatment with Everomus 0.25mg Tablet. Also, blood tests will be required to check your kidney function, liver function, blood glucose levels, and cholesterol levels.
Q. Why might my doctor give me a special mouthwash when I start Everomus 0.25mg Tablet?
Mouth ulcers and sores are common with Everomus 0.25mg Tablet, particularly during the first weeks of treatment. An alcohol-free mouthwash may be prescribed when treatment starts to reduce their likelihood and severity.
Q. What should I avoid using if I develop mouth sores?
Avoid mouthwashes or oral products containing alcohol, hydrogen peroxide, iodine, or thyme, as they may make mouth irritation worse.
Q. Can Everomus 0.25mg Tablet make me more likely to get infections?
Yes. Everomus 0.25mg Tablet suppresses immune activity and can increase the risk of bacterial, viral, fungal, and other infections. Contact your doctor promptly if you develop fever, chills, or otherwise feel unwell.

Content on this page was last updated on 12 November, 2026, by Dr. Mekhala Chandra (MD, MBBS)